

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: October 21, 2008 <i>(use as many sheets as necessary)</i>			<b>Application Number</b> 10/014,887 <b>Filing Date</b> 6/14/2000 <b>First Named Inventor</b> Geoffrey W. Krissansen <b>Art Unit</b> 1642 <b>Examiner Name</b> Lei Yao <b>Attorney Docket Number</b> 093397-0401		
Sheet	1	of	6		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
P1	3,678,077		07-18-1972	Nakanishi, et al.	
P2	4,602,034		07-22-1986	Briet, et al.	
P3	4,704,355		11-03-1987	Bernstein, et al.	
P4	5,126,129		06-30-1992	Wiltrot, et al.	
P5	5,464,826		11-07-1995	Grindey, et al.	
P6	6,174,873		01-16-2001	Wrenn, S. M.	
P7	6,194,454		02-27-2001	Dow, R. L.	
P8	6,806,257		10-19-2004	Lee, et al.	
P9	2001-0041713		11-15-2001	Waldstreicher, et al.	
P10	2004-0087611		05-06-2004	Baguley, et al.	
P11	2004-0204480		10-14-2004	Wilson, et al.	
P12	2005-0131059		06-16-2005	Wang, et al.	
P13	2006-0009505		01-12-2006	Baguley, et al.	
P14	2007-0060637		03-15-2007	Wilson, et al.	
P15	2007-0082937		04-12-2007	Baguley, et al.	
P16	2008-0070847		03-20-2008	Wilson, et al.	
P17	2008-0070848		03-20-2008	Wilson, et al.	
P18	2008-0070849		03-20-2008	Wilson, et al.	
P19	2008-0070886		03-20-2008	Wilson, et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document Serial Number-Kind Code <sup>2</sup> (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
U1	12/064,632		08-28-2006	Green, et al.	
U2	12/064,633		08-25-2006	Green, et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
F1	DE 2015265 A1		10-08-1970	Yoshitomi Pharmaceutical Industries, Ltd.	T <sup>6</sup> No

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/014,887	
Date Submitted: October 21, 2008 (use as many sheets as necessary)			Filing Date	6/14/2000	
Sheet	2	of	First Named Inventor	Geoffrey W. Krissansen	
			Art Unit	1642	
			Examiner Name	Lei Yao	
			Attorney Docket Number	093397-0401	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
F2	EP 0551200 A1		07-14-1993	National University of Singapore		
F3	GB 0121285.1		09-03-2001	Cancer Research Ventures, Ltd.		
F4	GB 0206839.3		05-01-2002	Cancer Research Ventures, Ltd.		
F5	GB 0225508.1		11-01-2002	Cancer Research Technology Ltd.		
F6	GB 0157387.7		08-25-2006	Antisoma Research Ltd.		
F7	GB 0157386.9		08-25-2006	Antisoma Research Ltd.		
F8	GB 0604114.9		03-02-2006	Antisoma Research Ltd.		
F9	NZ 506060		07-28-2000	Auckland Uniservices, Ltd.		
F10	WO 03/020259 A2		03-13-2003	Cancer Research Technology Ltd.		
F11	WO 03/080044		10-02-2003	Cancer Research Technology Ltd.		
F12	WO 04/039363		05-13-2004	Cancer Research Technology Ltd.		
F13	WO 05/027974 A1		03-31-2005	Cancer Research Technology Ltd.		
F14	WO 07/023302		03-01-2007	Antisoma PLC		
F15	WO 07/023307		03-01-2007	Antisoma PLC		
F16	WO 91/04014		04-04-1991	Syrogen, Inc.		
F17	WO 96/32418 A1		10-17-1996	Laboratoires OM S.A.		
F18	WO 96/36347A1		11-21-1996	Eli Lilly and Co.		
F19	WO 97/04761 A1		02-13-1997	Trustees of Boston University		
F20	WO 98/25615 A1		06-18-1998	Eli Lilly and Co.		
F21	WO 98/25616 A1		06-18-1998	Eli Lilly and Co.		
F22	WO 98/42334 A1		10-01-1998	Eli Lilly and Co.		
F23	WO 98/42345 A1		10-01-1998	Eli Lilly and Co.		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/014,887	
Date Submitted: October 21, 2008 (use as many sheets as necessary)			Filing Date	6/14/2000	
Sheet	3	of	First Named Inventor	Geoffrey W. Krissansen	
			Art Unit	1642	
			Examiner Name	Lei Yao	
			Attorney Docket Number	093397-0401	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>b</sup>
D1	ARBUCK, et al.; "An Overview of Topoisomerase I-Targeting Agents"; <i>Semin. Hematol.</i> 1998, 35(3 supp. 4):3-12.		
D2	ATWELL, et al.; "Potential Antitumor Agents. 60. Relationships between Structure and in Vivo Colon 38 Activity for 5-Substituted 9-Oxanthene-4-acetic Acid"; <i>J. Med. Chem.</i> (1990), 33:1375-1379.		
D3	AVASTIN. <a href="http://www.centerwatch.com/patient/drugs/drugs1851.html">Http://www.centerwatch.com/patient/drugs/drugs1851.html</a> , June 29, 2006.		
D4	BAGULEY, et al.; Poster Abstract 138, of abstracts book for the 16th EORTC-NCI-AACR 2004 meeting on "Molecular Targets and Cancer Therapeutics", Geneva, Switzerland (28 September to 1 October, 2004).		
D5	BAGULEY, et al.; "Potential of DMXAA combination therapy for solid tumors"; <i>Expert Rev. Anticancer Ther.</i> (2002), 2(5):593-603.		
D6	BAREFOOT, R.; "Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs"; <i>Journal of Chromatography B</i> (2001), 751:205-211.		
D7	BEGLEY, et al.; "The Blood-Brain-Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System"; <i>J. Pharm. Pharmacol.</i> (1996), 48:136-146.		
D8	BIBBY, et al.; "Flavone acetic acid - from laboratory to clinic and back"; <i>Anti-Cancer Drugs</i> (1993), 4:3-17.		
D9	BIBBY, et al.; "Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy"; <i>J. Natl. Cancer Inst.</i> (1989), 81:216-220.		
D10	BREM, et al.; "Interstitial chemotherapy with drug polymer implants for the treatment of recurring gliomas"; <i>J. Neurosurg.</i> (1991), 74:441-446.		
D11	CALABRESI, et al.; "The Pharmacological Basis of Therapeutics, Ninth Edition," (1996), Goodman & Gilman's The Pharmacological Basis of Therapeutics. Section X, Chemotherapy of Neoplastic Diseases, pages 1225-1229.		
D12	CHING, et al.; "The Anti-Tumour and Immune-Modulatory Activities of Flavone Acetic and Xanthone Acetic Acids"; 1990; N.P. Das (ed.), flavonoids in Biology and Medicine III. Proceedings of the 3rd International Symposium on Flavonoids in Biology and Medicine; 381-391.		
D13	COLOMA, et al.; "Transport across the primate Blood-Brain-Barrier of a genetically engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor"; <i>Pharmaceutical Research</i> (2000), 17(3):266-274.		
D14	CORBETT, et al.; "Activity of flavone acetic acid (NSC-347512) against solid tumors of mice"; <i>Investigational New Drugs</i> (1986), 4:207-220.		
D15	DJEHA, et al.; "Synergistic in vivo antitumor activity in lung and colon cancer xenografts with the vascular disrupting agent DMXAA combined with bevacizumab"; <i>Proc. Am. Assoc. Cancer. Res. Annual Meeting</i> , (2006), 47:55.		
D16	ECONOMOU, et al.; "Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo"; <i>Immunology</i> (1989), 67:514-519.		
D17	GALBRAITH, et al.; "Effects of 5,6-Dimethylxanthone-4-acetic acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-enhanced Magnetic Resonance Imaging"; <i>J. Clinical Oncology</i> (2002), 20(18):3826-3840.		
D18	GRAHAM, et al.; Fresh from the Pipeline: Cetuximab"; <i>Nature Reviews Drug Discovery</i> (2004), 3:549-550.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/014,887	
Date Submitted: October 21, 2008 (use as many sheets as necessary)			Filing Date	6/14/2000	
Sheet	4	of	First Named Inventor	Geoffrey W. Krissansen	
			Art Unit	1642	
			Examiner Name	Lei Yao	
			Attorney Docket Number	093397-0401	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>b</sup>
D19	GRIFFIOEN, et al.; "Angiogenesis Inhibitors Overcome Tumor Induced Endothelial Cell Anergy"; Int. J. Cancer (1999), 80:315-319.		
D20	JAMESON, et al.; "Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent"; British Journal of Cancer (2003), 88:1844-1850.		
D21	JAMESON, et al.; "Phase I Pharmacokinetic and Pharmacodynamic Study of 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA), A Novel Antivascular Agent"; Proc. Am. Soc. Clin Oncol. (2000), 19: 182a.		
D22	JOHNSON, et al.; "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials"; British J. of Cancer (2001), 84(10):1424-1431.		
D23	KELLAND, L.; "Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment"; Curr.Cancer. Ther. Rev. (2005), 1(1):1-9.		
D24	KROLL, et al.; "Improving Drug Delivery to Intracerebral Tumor and Surrounding Brain in a Rodent Model: A Comparison of Osmotic versus Bradykinin Modification of the Blood-Brain and/or Blood-Tumor Barriers"; Neurosurgery (1998), 43(4):879-886.		
D25	LANGER, R.; "New Methods of Drug Delivery"; Science (1990), 249:1527-1533.		
D26	MAIER, et al.; "In-Vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11"; Anti-Cancer Drugs (1997), 8:238-244.		
D27	MARNETT, L.J.; "Aspirin and Related Nonsteroidal Anti-inflammatory Drugs as Chemopreventive Agents against Colon Cancer"; Preventive Medicine 24,103-106 (1995)		
D28	MARONA, H.; "Synthesis and Properties of Some Xanthone-2-Alkylcarboxylic acids and Xanthone-2-Glycols"; Polish Journal of Chemistry, 54:2059 (1980).		
D29	MCKEAGE, et al.; "5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent"; Clin. Cancer Res. (2006), 12(6):1776-1784.		
D30	NAKAMURA, et al.; "Antitumor Effect of Recombinant Human Interleukin 1 Alpha against Murine Syngeneic Tumors"; Jpn. J. Cancer Research (1986), 77:767-773.		
D31	NAKANISHI, et al.; "Carboxylic Acids"; Chem. Abstr. 76:126784w (1972), (Abstract of Japan A-7,200,425)		
D32	NAKANISHI, et al.; "Studies of Anti-Inflammatory Agents XXXI; Studies on the Synthesis and Anti-Inflammatory Activity of Xanthenyl and Benzo-pyranopyridinylacetate acid Derivatives"; Yakugaku Zasshi (1976), 96:99-109.		Yes
D33	NEUWELT, et al.; "Increased Delivery of Tumor-specific Monoclonal Antibodies to Brain after Osmotic Blood-Brain-Barrier modification in Patients with Melanoma Metastatic to the Central Nervous System"; Neurosurgery (1987), 20(6):885-895.		
D34	NISHINO, et al.; "Oxidation of 9-Xanthenones with Lead (IV) Acetate. Formation of Di-gamma-lactones"; Bull. Chem. Soc. Jpn. (1983), 56:2847-48.		
D35	NISHINO, et al.; "Regionselective Carboxylation of 9-Xanthenones with Manganese (III) Acetate." Bull. Chem. Soc. Jpn. (1983), 56:474-480.		
D36	O'REILLY, et al.; "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth"; Cell (1997), 88:277-285.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/014,887	
Date Submitted: October 21, 2008 (use as many sheets as necessary)			Filing Date	6/14/2000	
Sheet	5	of	First Named Inventor	Geoffrey W. Krissansen	
			Art Unit	1642	
			Examiner Name	Lei Yao	
			Attorney Docket Number	093397-0401	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
	D37	PECKHAM, et al.; "Oxford Textbook of Oncology". Oxford University Press, Vol 1. p.451, 1995.	
	D38	PLOWMAN, et al.; "Flavone Acetic Acid: A Novel Agent with Preclinical Antitumor Activity Against Colon Adenocarcinoma 38 in Mice"; Cancer Treatment Reports (1986), 70(5):631-635.	
	D39	PTCL. Chemical and Other Safety Information. "ptcl.chem.ox.ac.uk/MSDS"	
	D40	REWCASTLE, et al.; "Potential Antitumor Agents. 62. Structure-Activity Relationships for Tricyclic Compounds Related to the Colon Tumor Active Drug 9-Oxo-9H-xanthene-4-acetic Acid"; J. Med. Chem. (1991), 34:491-496.	
	D41	RIECKMANN, et al.; "Okadaic Acid is a potent inducer of AP-1, NF-kappa-B, and Tumor-Necrosis Factor-alpha in Human B Lymphocytes"; Biochem. Biophys. Res. Commun. (1992), 187(1):51-57.	
	D42	RUSTIN et al.; "5,6-Dimethylxanthene-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study"; British Journal of Cancer (2003), 88:1160-1167.	
	D43	RUSTIN et al.; "Impact on Tumour Perfusion Measured by Dynamic Magnetic Resonance Imaging (MRI), in the Phase I Trial of 5,6-dimethylxanthene-4-acetic Acid (DMXAA)"; Proc. 10th NCI-EORTC Symp. New Drugs (1998), 10:126.	
	D44	SALTIEL, E.; "Erlotinib". <a href="http://www.medicinenet.com/erlotinib/article.htm">Http://www.medicinenet.com/erlotinib/article.htm</a> . Nov 28, 2004.	
	D45	SALTIEL, E.; "Gefitinib". <a href="http://www.medicinenet.com/gefitinib/article.htm">Http://www.medicinenet.com/gefitinib/article.htm</a> . June 22, 2005.	
	D46	SAUSVILLE, et al.; "Contributions of human tumor xenografts to anticancer drug development"; Cancer Research (2006), 66(7):3351-3354.	
	D47	SHOEMAKER, et al.; "Pleiotropic Resistance and Drug Development"; Cancer Drug Resistance (1986), 143-149.	
	D48	SHOWALTER, H.; "Potential Antitumor Agents. 61. Structure-Activity Relationships for In Vivo Colon 38 Activity Among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids"; Chemtracts: Org. Chem. (1991), 4(2): 168-171. Commentary of REWCASTLE: J. Med. Chem. (1991), 34:217-222.	
	D49	SIEMANN, et al.; "Enhanced Antitumor Efficacy through the combination of Vascular Targeting Agents and Conventional Anticancer Drugs"; Proceedings of the American Association for Cancer Research (2000), 41:525.	
	D50	SIEMANN, et al.; "Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy"; Int. J. Cancer (2002), 99:1-6.	
	D51	SILM, et al.; "Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthene-4-acetic acid (DMXAA)"; Cancer Chemother Pharmacol (2003), 51:43-52.	
	D52	SIMONE, et al.; "Oncology". Cecil Text Book of Medicine. 20th Edition Vol 1, W. B. Saunders Company. 1997, p1004-1010.	
	D53	TEMSAMANI, et al.; "Brain drug delivery technologies: novel approaches for transporting therapeutics"; Pharm. Sci. Technology Today (2000), 3(5):155-162.	
	D54	TYLE, P.; "Iontophoretic Devices for Drug Delivery"; Pharmaceutical Research (1986), 3(6):318-326.	
	D55	VAN MOERSEL, et al.; "Combination Chemotherapy Studies with Gemcitabine and Etoposide in Non-Small Cell Lung and Ovarian Cancer Cell Lines"; Biochemical Pharmacology (1999), 57:407-415.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/014,887	
Date Submitted: October 21, 2008 (use as many sheets as necessary)			Filing Date	6/14/2000	
Sheet	6	of	First Named Inventor	Geoffrey W. Krissansen	
			Art Unit	1642	
			Examiner Name	Lei Yao	
			Attorney Docket Number	093397-0401	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
	D56	WESTLAND, et al.; "Activated non-neuronal specific T cells open the blood-brain-barrier to circulating antibodies"; <i>Brain</i> (1999), 122:1283-1291.	
	D57	WIESENTHAL, "Is one 'sensitive' drug better than another? Can you detect drug synergy? What are the best drug combinations?" <a href="http://weisenthal.org/feedback.html">http://weisenthal.org/feedback.html</a> , 2/04/2002.	
	D58	WILKINSON, et al.; "Tamoxifen (Novaldex) Therapy - Rationale for Loading Dose Followed by Maintenance Dose for Patients with Metastatic Breast Cancer"; <i>Cancer Chemotherapy Pharmacol.</i> (1982), 10:33-35.	
	D59	WOUTERS, et al.; "Hypoxia as a target for combined modality treatments"; <i>European J. Cancer</i> (2002), 38:240-257.	
	D60	ZAHARKO, et al.; "Therapeutic and Pharmacokinetic Relationships of Flavone Acetic Acid: An Agent with Activity Against Solid Tumors"; <i>Cancer Treatment Reports</i> (2002), 70(12):1415-1421.	
	D61	ZHANG, et al.; "Conjugation of brain-derived neurotrophic factor to a blood-brain-barrier resistant drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin"; <i>Brain Research</i> (2001), 889:49-56.	
	D62	ZHAO, et al.; "Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling"; <i>Clinical Cancer Research</i> (2003), 9:6545-6550.	
	D63	ZHAO, et al.; "Oral activity and pharmacokinetics of 5,6-dimethylxanthenone acetic acid (DMXAA) in mice"; <i>Cancer Chemother. Pharmacol.</i> (2002), 49:20-26.	
	D64	ZHOU, et al.; "Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes"; <i>J. Clin. Pharmacol.</i> (2001), 52:129-136.	
	D65	ZWI, et al.; "Blood Flow Failure as a Major Determinant in the Antitumor Action of Flavone Acetic Acid"; <i>J. Natl. Cancer Inst.</i> (1989), 81:1005-1013.	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.